92 related articles for article (PubMed ID: 20127944)
1. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Youssoufian H; Rowinsky EK; Tonra J; Li Y
Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
[TBL] [Abstract][Full Text] [Related]
2. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
[TBL] [Abstract][Full Text] [Related]
4. Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
Yamamoto Y; Tsuzuki S; Akahori Y; Ukai Y; Sumitomo M; Murayama Y; Yamamoto K; Inaguma Y; Tokuda M; Abe A; Akatsuka Y; Emi N; Kurosawa Y
Cancer Sci; 2012 Feb; 103(2):350-9. PubMed ID: 22049994
[TBL] [Abstract][Full Text] [Related]
5. Investigational drugs targeting FLT3 for leukemia.
Ustun C; DeRemer DL; Jillella AP; Bhalla KN
Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
[TBL] [Abstract][Full Text] [Related]
6. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
Li Y; Li H; Wang MN; Lu D; Bassi R; Wu Y; Zhang H; Balderes P; Ludwig DL; Pytowski B; Kussie P; Piloto O; Small D; Bohlen P; Witte L; Zhu Z; Hicklin DJ
Blood; 2004 Aug; 104(4):1137-44. PubMed ID: 15105287
[TBL] [Abstract][Full Text] [Related]
7. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
8. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
10. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.
Williams B; Atkins A; Zhang H; Lu D; Jimenez X; Li H; Wang MN; Ludwig D; Balderes P; Witte L; Li Y; Zhu Z
Leukemia; 2005 Aug; 19(8):1432-8. PubMed ID: 15931264
[TBL] [Abstract][Full Text] [Related]
11. FLT3 inhibition in acute myeloid leukaemia.
Knapper S
Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
[TBL] [Abstract][Full Text] [Related]
12. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.
Hofmann M; Große-Hovest L; Nübling T; Pyż E; Bamberg ML; Aulwurm S; Bühring HJ; Schwartz K; Haen SP; Schilbach K; Rammensee HG; Salih HR; Jung G
Leukemia; 2012 Jun; 26(6):1228-37. PubMed ID: 22289926
[TBL] [Abstract][Full Text] [Related]
13. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Shabbir M; Stuart R
Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
[TBL] [Abstract][Full Text] [Related]
14. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Giles FJ
Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
[TBL] [Abstract][Full Text] [Related]
15. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Fesler MJ; Richart JM; Petruska PJ
Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
[No Abstract] [Full Text] [Related]
16. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
17. FLT3 antibody-based therapeutics for leukemia therapy.
Li Y; Zhu Z
Int J Hematol; 2005 Aug; 82(2):108-14. PubMed ID: 16146840
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.
Nishiyama U; Yoshino T; Ozai M; Yoshioka R; Fujisawa M; Ogasawara Y; Kitahori M; Yoshioka E; Kubo K; Komeno Y; Kurokawa M; Ogawa S; Chiba S; Osawa T; Kuwaki T; Hirai H; Miwa A
Leuk Res; 2006 Dec; 30(12):1541-6. PubMed ID: 16603240
[TBL] [Abstract][Full Text] [Related]
19. Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT; Levis M
Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
[TBL] [Abstract][Full Text] [Related]
20. A substrate peptide for the FLT3 receptor tyrosine kinase.
Böhmer FD; Uecker A
Br J Haematol; 2009 Jan; 144(1):127-30. PubMed ID: 19016738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]